PL378566A1 - Ligandy dla białek wiążących TGF-beta i ich zastosowania - Google Patents
Ligandy dla białek wiążących TGF-beta i ich zastosowaniaInfo
- Publication number
- PL378566A1 PL378566A1 PL378566A PL37856604A PL378566A1 PL 378566 A1 PL378566 A1 PL 378566A1 PL 378566 A PL378566 A PL 378566A PL 37856604 A PL37856604 A PL 37856604A PL 378566 A1 PL378566 A1 PL 378566A1
- Authority
- PL
- Poland
- Prior art keywords
- tgf
- complex
- beta binding
- ligands
- binding proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45525303P | 2003-03-14 | 2003-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL378566A1 true PL378566A1 (pl) | 2006-05-02 |
Family
ID=33029975
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL378566A PL378566A1 (pl) | 2003-03-14 | 2004-03-12 | Ligandy dla białek wiążących TGF-beta i ich zastosowania |
| PL04720380T PL1608399T3 (pl) | 2003-03-14 | 2004-03-12 | Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04720380T PL1608399T3 (pl) | 2003-03-14 | 2004-03-12 | Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7226902B2 (pl) |
| EP (1) | EP1608399B1 (pl) |
| JP (1) | JP4660471B2 (pl) |
| AT (1) | ATE540977T1 (pl) |
| AU (1) | AU2004222317B2 (pl) |
| CA (1) | CA2519131C (pl) |
| CY (1) | CY1112797T1 (pl) |
| DK (1) | DK1608399T3 (pl) |
| ES (1) | ES2379689T3 (pl) |
| MX (1) | MXPA05009805A (pl) |
| NZ (1) | NZ542587A (pl) |
| PL (2) | PL378566A1 (pl) |
| PT (1) | PT1608399E (pl) |
| SI (1) | SI1608399T1 (pl) |
| WO (1) | WO2004082608A2 (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2261335B1 (en) | 1998-11-27 | 2017-06-14 | UCB Pharma S.A. | Compositions and methods for increasing bone mineralisation |
| BRPI0411552A (pt) | 2003-06-16 | 2006-08-01 | Celltech R & D Inc | anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea |
| US8461155B2 (en) * | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| WO2007028212A1 (en) * | 2005-09-08 | 2007-03-15 | Apollo Life Sciences Limited | Noggin and chimeric molecules thereof |
| WO2008042754A2 (en) | 2006-10-02 | 2008-04-10 | Sea Lane Biotechnologies, Llc | Design and construction of diverse synthetic peptide and polypeptide libraries |
| WO2008133722A2 (en) * | 2006-11-10 | 2008-11-06 | Ucb Pharma S.A. | Anti human sclerostin antibodies |
| EP2423226A3 (en) * | 2006-11-10 | 2012-05-30 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| EP2114435A1 (en) * | 2007-02-02 | 2009-11-11 | Novartis AG | Modulators of sclerostin binding partners for treating bone-related disorders |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| JP2011506483A (ja) * | 2007-12-14 | 2011-03-03 | アムジエン・インコーポレーテツド | 抗スクレロスチン抗体を用いた骨折の治療方法 |
| EP2349332B1 (en) * | 2008-11-13 | 2019-10-23 | The General Hospital Corporation | Methods and compositions for regulating iron homeostasis by modulation bmp-6 |
| KR101163171B1 (ko) * | 2009-01-20 | 2012-07-19 | (주)케어젠 | 노긴?유래 펩타이드 및 그의 용도 |
| SG185465A1 (en) | 2010-05-14 | 2012-12-28 | Amgen Inc | High concentration antibody formulations |
| CA2828000A1 (en) | 2011-03-01 | 2012-09-07 | Amgen Inc. | Bispecific binding agents |
| AU2012236962B2 (en) | 2011-03-25 | 2017-05-11 | Amgen Inc. | Anti-sclerostin antibody crystals and formulations thereof |
| CA2842432C (en) | 2011-08-04 | 2022-10-04 | Amgen Inc. | Method for treating bone gap defects |
| MX354270B (es) | 2011-12-28 | 2018-02-21 | Amgen Inc | Uso de un anticuerpo antiesclerostina en el tratamiento de la pérdida ósea alveolar. . |
| CN104619342A (zh) | 2012-07-05 | 2015-05-13 | Ucb医药有限公司 | 骨疾病的治疗 |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| JP2020502218A (ja) | 2016-12-21 | 2020-01-23 | メレオ バイオファーマ ３ リミテッド | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
| MX2020010092A (es) | 2018-03-30 | 2020-10-28 | Amgen Inc | Variantes de anticuerpo c-terminales. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5846770A (en) * | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
| CA2220912A1 (en) | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
| US5989909A (en) * | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
| WO1998046588A2 (en) * | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| US6075007A (en) * | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
| AR023301A1 (es) | 1998-03-30 | 2002-09-04 | Dow Agrosciences Llc | Metodo para modificar gencticamente una planta para que la misma produzca una semilla vegetal con niveles alterados de rcidos grasos saturados |
| EP2261335B1 (en) | 1998-11-27 | 2017-06-14 | UCB Pharma S.A. | Compositions and methods for increasing bone mineralisation |
| MXPA02008506A (es) * | 2000-03-02 | 2002-12-13 | Amgen Inc | Moleculas semejantes a chordin-2 y sus usos. |
-
2004
- 2004-03-12 PL PL378566A patent/PL378566A1/pl unknown
- 2004-03-12 SI SI200431852T patent/SI1608399T1/sl unknown
- 2004-03-12 NZ NZ542587A patent/NZ542587A/en not_active IP Right Cessation
- 2004-03-12 AT AT04720380T patent/ATE540977T1/de active
- 2004-03-12 JP JP2006507118A patent/JP4660471B2/ja not_active Expired - Fee Related
- 2004-03-12 PL PL04720380T patent/PL1608399T3/pl unknown
- 2004-03-12 MX MXPA05009805A patent/MXPA05009805A/es active IP Right Grant
- 2004-03-12 EP EP04720380A patent/EP1608399B1/en not_active Expired - Lifetime
- 2004-03-12 PT PT04720380T patent/PT1608399E/pt unknown
- 2004-03-12 ES ES04720380T patent/ES2379689T3/es not_active Expired - Lifetime
- 2004-03-12 DK DK04720380.7T patent/DK1608399T3/da active
- 2004-03-12 US US10/799,162 patent/US7226902B2/en not_active Expired - Fee Related
- 2004-03-12 CA CA2519131A patent/CA2519131C/en not_active Expired - Fee Related
- 2004-03-12 AU AU2004222317A patent/AU2004222317B2/en not_active Ceased
- 2004-03-12 WO PCT/US2004/007565 patent/WO2004082608A2/en active Application Filing
-
2012
- 2012-04-09 CY CY20121100348T patent/CY1112797T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1608399T1 (sl) | 2012-05-31 |
| JP4660471B2 (ja) | 2011-03-30 |
| WO2004082608A9 (en) | 2005-03-17 |
| DK1608399T3 (da) | 2012-04-02 |
| EP1608399A2 (en) | 2005-12-28 |
| US7226902B2 (en) | 2007-06-05 |
| AU2004222317A1 (en) | 2004-09-30 |
| WO2004082608A2 (en) | 2004-09-30 |
| US20050085418A1 (en) | 2005-04-21 |
| PT1608399E (pt) | 2012-04-13 |
| MXPA05009805A (es) | 2006-04-18 |
| PL1608399T3 (pl) | 2012-09-28 |
| NZ542587A (en) | 2008-05-30 |
| CA2519131C (en) | 2014-07-08 |
| ES2379689T3 (es) | 2012-04-30 |
| WO2004082608A3 (en) | 2005-01-20 |
| JP2006522103A (ja) | 2006-09-28 |
| ATE540977T1 (de) | 2012-01-15 |
| AU2004222317B2 (en) | 2010-08-19 |
| CA2519131A1 (en) | 2004-09-30 |
| EP1608399B1 (en) | 2012-01-11 |
| CY1112797T1 (el) | 2016-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL378566A1 (pl) | Ligandy dla białek wiążących TGF-beta i ich zastosowania | |
| CY1124802T1 (el) | Δεσμευτικοι παραγοντες σκληροστινης | |
| RS20050934A (en) | Antibodies specific for sclerostin and methods fo r increasing bone mineralization | |
| MEP3108A (xx) | Kompozicije i postupci za povećanje mineralizacije kostiju | |
| MY174493A (en) | Binding agents | |
| MX2007008017A (es) | Polipeptidos que se ligan a br3 y usos de los mismos. | |
| EA200700847A1 (ru) | Материалы, связывающие прионные белки, и способы их применения | |
| UA97473C2 (ru) | Выделенное антитело, которое связывается с her-3, и его применение | |
| WO2006113681A3 (en) | Plant-derived elastin binding protein ligands and methods of using the same | |
| TW200745159A (en) | IL-6 binding proteins | |
| WO2006087163A3 (en) | Novel in vitro methods for studying receptors recognizing volatile compounds | |
| EA200800205A1 (ru) | Кальций-пептидный компонент | |
| WO2003060067A3 (en) | P85-alpha nucleic acids, polypeptides and related methods | |
| EA200500624A1 (ru) | Промотор для il-18bp, его получение и применение | |
| TW200718711A (en) | Polypeptides that bind BR3 and uses thereof | |
| WO2006008266A3 (en) | Factor xi-binding proteins | |
| WO2007050554A3 (en) | Methods for identifying compounds that modulate phb domain protein activity and compositions thereof | |
| WO2004070347A3 (en) | Screening for modulators of fat storage | |
| UA115859C2 (uk) | Розчинний поліпептид, який зв'язує активін а, та композиція, що його містить | |
| WO2005040208A3 (en) | Peptides derived from heat shock proteins binding toll-like receptors 2 and 4 and their use |